Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782332 | 1.00 | ANPEP (0.57) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL5658130 | 1.00 | ANPEP (0.57) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL8069933 | 1.00 | ANPEP (0.57) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL27487680 | 0.89 | ANPEP (0.53) | ANPEPALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL7284516 | 0.89 | ANPEP (0.53) | ANPEPALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL10448479 | 0.89 | ANPEP (0.53) | ANPEPALDH1A1MEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL8617719 | 0.87 | ANPEP (0.52) | ANPEPMEN1KMT2ASIGMAR1 | |
| SCHEMBL4170192 | 0.87 | TRPM8 (0.55) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL4166663 | 0.87 | TRPM8 (0.55) | ANPEPALDH1A1MEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL27488757 | 0.87 | ANPEP (0.52) | ANPEPMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107365368-B | Asperphenamate synthesis related protein, coding gene and application thereof | 中国科学院微生物研究所 | 2020-09-08 | — | — | CN | claimed |
| CN-107365368-A | Asperphenamate synthesis associated proteins and its encoding gene and application | 中国科学院微生物研究所 | 2017-11-21 | — | — | CN | claimed |
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-12-08 | — | — | US | disclosed |
| CN-107365368-B | Asperphenamate synthesis related protein, coding gene and application thereof | 中国科学院微生物研究所 | 2020-09-08 | — | — | CN | disclosed |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2018-08-09 | — | — | US | disclosed |
| CN-107365368-A | Asperphenamate synthesis associated proteins and its encoding gene and application | 中国科学院微生物研究所 | 2017-11-21 | — | — | CN | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| CN-1960965-A | Synthesis of amino-alkoxy-heptanoic alkyl ester | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | IGF1R, IGFBP1, IGFBP5 | ANPEP 1782/4885ALDH1A1 532/4885MEN1 185/4885 |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ANPEP 2321/4885ALDH1A1 2916/4885MEN1 2933/4885 |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | ALDH7A1, BCAT1, BCAT2 | ANPEP 40/4885ALDH1A1 88/4885MEN1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.